Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis

References

• Wilhelm S CD: Bay 43-9006: Preclinical data. Curr Pharm Des 2002;8:2255–7.
   PubMed Web of Science ®Google Scholar
• Strumberg D RH, Hilger R, et al. Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor bay 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965–72
   PubMed Web of Science ®Google Scholar
• Ratain M ET, Stadler W, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505–12
   PubMed Web of Science ®Google Scholar
• Gatzemeier U. GB FF, Simantov R, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. ASCO annual meeting Atlanta, Georgia. J Clin Oncol 2006; 24: 364s (Abstract #7002)
   Google Scholar
• Ghassan K LS, Sergio R, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293–300
   PubMedGoogle Scholar
• Steinbild S BF, Gmehling D, et al. Phase I study of sorafenib, a raf kinase and vegfr inhibitor, combined with irinotecan in advanced solid tumors. Proc Am Soc Clin Oncol 2005; 23: 3115a
   Google Scholar
• Eisen T AT, Gore ME, et al. Phase I trial of sorafenib combined with dacarbazine in metastatic melanoma patients. Proc Am Soc Clin Oncol 2005; 23: 7508a
   Google Scholar
• Burgdorf W GW, Ganick R. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous lekemia. Ann Intern Med 1982; 97: 61–2
   PubMed Web of Science ®Google Scholar
• Lokich J MC. Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 789–800
   PubMedGoogle Scholar
• MetaAnalysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537–41.
   PubMedGoogle Scholar
• Escudier B ET, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 2007; 356: 125–34
   PubMed Web of Science ®Google Scholar
• NCI: Common toxicity criteria version II or III. http://ctepcancergov/reporting/ctchtml 2006.
   Google Scholar
• DerSimonian R LN. Meta-analysis in clinical trials. Control Clin Trial 1986; 7: 177–88
   PubMedGoogle Scholar
• Lau J IJ, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820–6
   PubMed Web of Science ®Google Scholar
• Eiesen T AT, Flaherty K, et al. Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95: 581–6
   PubMedGoogle Scholar
• Escudier B, Sc DT, Staehler M, et al. Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma. ASCO annual meeting Atlanta, Georgia 2006
   Google Scholar
• Wu S EP CS, P. M. Arlen, et al. Bay43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgen-independent prostate cancer despite rises in serum psa levels. 2006 Prostate Cancer Symposium San Fransisco, 2006 Abstract No:259.
   Google Scholar
• Escudier B Sc, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, et al. Randomized phase II trial of sorafenib vs interferon in treatment-naive patients with advanced renal cell carcinoma. ASCO annual meeting, AtlantaGeorgia 2006
   Google Scholar
• D'Adamo DR KM, Schuetze S, et al. A multicenter phase II trial of oral sorafenib in non-gist sarcomas ctep trial #7060. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:545s (Abstract #10001).
   Google Scholar
• Llovet J RS, Mazzaferro V, et al. Sorafenib improves survival in hepatocellular carcinoma: Results of a phase III randomized, placebo-controlled trial. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:1s (Abstract #LBA1).
   Google Scholar
• Figlin R SW, McDermott D, et al. The advanced renal cell carcinoma sorafenib(arccs) expanded access program in North America: Safety and efficacy. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:237s (Abstract #5011).
   Google Scholar
• Hobday T RJ, Holen K, et al. A phase II trial of sorafenib in patients with metastatic neuroendocrine tumors(net): A phase II consortium (p2c) study. ASCO annual meeting Chicago, Illinois. J Clin Oncol 2007;25:199s (Abstract #4504).
   Google Scholar
• Strumberg D AA, Hirte H, et al. Pooled safety analysis of bay 43–9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. Eur J Cancer 2006; 42: 548–56
   PubMed Web of Science ®Google Scholar
• Mrozek-Orlowski M FD, Sandborn H, et al. Capecitabine: Nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999; 26: 753–62
   PubMedGoogle Scholar
• Jacobi U WE, Schulze P. Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome?. Ann Oncol 2005; 16: 1210–1
   PubMed Web of Science ®Google Scholar
• Lai S KT, Lacouture M. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007; 25: 341
   PubMedGoogle Scholar
• Eskens F VJ. The clinical toxicity profile of vascular endothelial growth factor(vegf) and vascular endothelial growth factor receptor(vegfr) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42: 3127–39
   PubMed Web of Science ®Google Scholar
• Robert C SJ, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491–500
   PubMed Web of Science ®Google Scholar
• Azad N PE, Kohn E, et al. Increased efficacy and toxicity with combination anti-vegf therapy using sorafenib and bevacizumab. ASCO Annual Meeting Atlanta, Georgia. J Clin Oncol 2006; 24: 3004
   Web of Science ®Google Scholar
• Erber R TA, Katsen A, et al. Combined inhibition of vegf and pdgf signaling enforces tumor vessel regression by interering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 2004; 18: 338–40
   PubMed Web of Science ®Google Scholar
• Tsai K YC, Kuo T, et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 24: 5786–8
   PubMedGoogle Scholar
• Lorusso D DSA, Carone V, et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot syndrome’). Ann Oncol 2007.
   Google Scholar
• Ponten F RZ, Nister M, et al. Epithelial-stromal interactions in basal cell cancer: The pdgf system. J Invest Dermatol 1994; 102: 304–9
   PubMed Web of Science ®Google Scholar
• Lammie A DM, Gerald W, et al. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994; 42: 1417–25
   PubMed Web of Science ®Google Scholar
• Morita E LD, Sugiyama M, et al. Expression of c-kit ligand in human keratinocytes. Arch Dermatol Res 1994; 286: 273–7
   PubMed Web of Science ®Google Scholar
• Kawamura T DN, Shimizu A, et al. Imatinib mesylate causes palmoplantar hyperkeratosis in 3 patients with chronic myeloid leukemia. Br J Dermatol 2006; 154: 1199–219
   PubMedGoogle Scholar
• Hainsworth JD SJ, Spigel DR, et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma (rcc): A minnie pearl cancer research network phase I/II trial. ASCO Annual Meeting Orlando. 2005 Abstract # 4542.
   Google Scholar
• Gerbrecht B. Current Canadian experience with capecitabine: Partnering with patients to optimize therapy. Cancer Nurs 2003; 26: 161–7
   PubMedGoogle Scholar
• Bayer. Nexavar prescribing information, 8/06 available at http://www.Nexavar.Com/wt/page/index. 2006.
   Google Scholar
• Bertelli G GA, Forno G, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. J Clin Oncol 1995; 13: 2851–5
   PubMed Web of Science ®Google Scholar
• Eng C MA, Fleming G, et al. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol 2001; 12: 1743–7
   PubMedGoogle Scholar
• Fabian C MR, Lavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia assoicated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57–63
   PubMed Web of Science ®Google Scholar
• Vukelja S BW, Burris H, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993; 85: 1432–3
   PubMed Web of Science ®Google Scholar
• Drake R LW, King M, et al. Oral dexamethasone attenuates pld-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004; 94: 320–4
   PubMed Web of Science ®Google Scholar
• Jaber R DW, Wu S. Dramatic improvement of palmar plantar erythrodysesthesia(ppe) with oral prednisone. Ann Oncol 2007; Elecronic letter.
   Google Scholar
• Kingsley E. 5-flourouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 1994;120:813 (Abstract).
   PubMed Web of Science ®Google Scholar
• Kara I SB, Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006; 15: 414–24
   PubMed Web of Science ®Google Scholar
• Lin E MJ, Ayers G. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity (Abstract). Oncology 2002; 16: 31–7
   PubMed Web of Science ®Google Scholar
• Panares R GAea. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Therapy 2007; 4: 433–45
   Google Scholar
• Wolf D TH, Rumpold H, et al. The kinase inhibitor imatinib--an immunosuppressive drug?. Curr Cancer Drug Target 2007; 3: 251–8
   Google Scholar
• Morabito A DME, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist 2006; 11: 753–64
   PubMed Web of Science ®Google Scholar
• Motzer R HT, Tomczak P, et al. Sunitinib vs interferon alfa in metastatic renal cell cancer. NEJM 2007; 356: 115–24
   PubMed Web of Science ®Google Scholar
• Goodman V RE, Dagher R, et al. Approval summary: Sunitinib for the treatment of imatinib refractory or intolerance in gastrointestinal stromal tumors and advanced renal cell cancer. Clin Cancer Res 2007; 13: 1367–73
   PubMed Web of Science ®Google Scholar